Randomized Double-Blind Placebo-Controlled Phase 2 Study of Luvadaxistat for Cognitive Impairment Associated with Schizophrenia

Phase 2, randomised, double-blind trial in schizophrenia comparing Luvadaxistat (double-blind then open-label) with Placebo (double-blind then open-label luvadaxistat) (2 arms). Primary endpoint: Change from baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) composite score. Started Nov 2022; status: completed.